Apollo Hospitals reports 14% YoY revenue growth in Q3FY25; PAT surges 52%
Hyderabad: Apollo Hospitals posted a 14% year-on-year (YoY) increase in revenue for Q3 FY25, reaching Rs 5,527 crore, Mint reported.
The Healthcare Services (HCS) segment contributed Rs 2,785 crore, reflecting a 13% YoY rise, while Apollo Health & Lifestyle Limited (AHLL) posted Rs 390 crore, up 15% YoY.
Apollo HealthCo, which includes pharmacy distribution and digital health services, recorded Rs 2,352 crore in revenue, also growing 15% YoY. The gross merchandise value (GMV) of Apollo 24/7 stood at Rs 760 crore.
Strong Profit and EBITDA Growth
The company’s consolidated EBITDA for the quarter surged 24% YoY to Rs 762 crore. The HCS segment reported Rs 671 crore, marking a 14% YoY increase, while AHLL’s EBITDA rose 32% YoY to Rs 34 crore. Apollo HealthCo recorded an EBITDA of Rs 57 crore.
Profit after tax (PAT) saw a significant 52% YoY jump to Rs 372 crore, compared to Rs 245 crore in Q3 FY24. The hospital network had 7,996 operating beds (excluding AHLL & managed beds) as of December 31, 2024. Overall hospital occupancy rose to 68% from 66% in the same period last year, driven by an increase in patient flow.
Apollo Hospitals Enterprise Chairman Prathap C Reddy said, "The results reflect our growth story that underlines our purpose of healing India and touching more than a billion lives. From Mumbai to Varanasi and Chennai to Gurugram, we are committed to ensuring that quality healthcare is not a privilege but a fundamental right for all."
Expansion plans and strategic partnerships
The company announced an interim dividend of Rs 9 per share (180% of the face value of Rs 5 each) for FY25, with February 15, 2025, as the record date.
Apollo Hospitals is on track to add 3,512 beds over the next 3 to 4 years, beginning FY26. It also achieved a milestone in cardiac care, having completed over 1,000 robotic cardiac surgeries across Bangalore and Chennai.
Meanwhile, Apollo partnered with Microsoft to advance healthcare through AI and digital innovation, focusing on disease progression and genomics.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
